Stock News
Feelin’ the Dip? Here’s Why Oceaneering International (OII) Might Be Your Next Smart Buy!
Is Oceaneering International a Stock to Watch? The Technical Perspective Oceaneering International (OII) has recently been identified as an oversold stock, signaling that heavy selling pressure may have come to an end. This could potentially lead to a trend reversal in the near future. Additionally, there is strong agreement among Wall Street analysts in revising…
Important Update for Investors: Levi & Korsinsky Continues Investigation into Possible Securities Law Violations at Keros Therapeutics Inc. (KROS)
Investigation Commenced into Keros Therapeutics, Inc. December 20, 2024 Levi & Korsinsky has announced that it is investigating Keros Therapeutics, Inc. (NASDAQ:KROS) for potential violations of federal securities laws. This investigation comes in response to a press release issued by Keros on December 12, 2024, in which the company disclosed that it has halted dosing…
Vertical Aerospace Crushes Third Quarter Finances: A Rollercoaster Ride of Numbers and Laughs!
Welcome to the Future of Aviation A Look at Vertical Aerospace’s Third Quarter Financial Results Hey there aviation enthusiasts! Have you heard the latest news from Vertical Aerospace Ltd.? The global aerospace and technology company just announced its financial results for the third quarter ended September 30, 2024. Exciting stuff, right? Let’s dive into the…
Breaking News: Quoin Pharmaceuticals Sets Price for $6.8 Million Public Offering in 2024
Quoin Pharmaceuticals Ltd. Announces Pricing of Public Offering About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical stage, specialty pharmaceutical company that focuses on rare and orphan diseases. The company is dedicated to developing innovative solutions to help patients with these challenging conditions. Public Offering Details On December 20, 2024, Quoin Pharmaceuticals…
Vanda Pharmaceuticals Receives Orphan Drug Designation for VGT-1849A: A Promising Treatment for Polycythemia Vera
Vanda Pharmaceuticals Receives Orphan Drug Designation for VGT-1849A in Treatment of Polycythemia Vera Introduction Washington, Dec. 20, 2024 – Vanda Pharmaceuticals Inc. (Vanda) has recently made groundbreaking strides in the treatment of polycythemia vera (PV) with the announcement of the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation for VGT-1849A. This selective antisense…
Breaking News: Monopar Therapeutics Inc. Drops Mic with $40 Million Public Offering and Private Placement Shenanigans!
Getting Warm and Cozy with Monopar Therapeutics Inc. Catching up on the Latest News Did you hear the latest scoop? Monopar Therapeutics Inc., a biotechnology company that always keeps us on our toes, has just announced some big news that has the medical community abuzz. They’ve priced an underwritten registered offering of their common stock,…
Eightco Successfully Secures Non-Dilutive Capital and Extends Debt for Second Time
$7.2 Million Debt Extension and $3.1 Million New Financing to Fuel Expansion Plans for 2025 Eightco Holdings Inc. Announces Debt Restructuring and New Financing Easton, PA, Dec. 20, 2024 (GLOBE NEWSWIRE) — Eightco Holdings Inc. (NASDAQ: OCTO) (the “Company” or “Eightco”) today announced that its wholly-owned subsidiary, Forever 8 Fund, LLC (“Forever 8”), completed a…
Proactive Investors: Your Source for Professionally Educated, Profit-Focused, and Intense Company News
Giyani Metals Corp Provides Update on Demonstration Plant Commissioning Introduction Giyani Metals Corp (TSX-V:EMM, OTC:CATPF) has recently provided an update on the commissioning of its Demonstration Plant (Demo Plant) in Johannesburg, South Africa, as part of its K.Hill battery-grade manganese project in Botswana. The company has announced that the plant is nearing completion of commissioning,…